NANOBIOTIX Provides Business Update and Reports Full Year
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Source: globenewswire.com
📰 Single Agent Activated News
Single Agent Activated News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Single Agent Activated. Real-time updates on events, politics, business and more.
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces...
Source: marketscreener.com
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3Prolonged survival in Study 102 reinforces pivotal NANORAY-312 trial design in head and
Source: eagletribune.com
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
$2.5 billion global licensing, co-development, and commercialization agreement expands worldwide potential of novel radioenhancer NBTXR316.9 months median progression free survival (mPFS) and 23.1 months median overall survival (mOS) following radiotherapy-activated
Source: elpasoinc.com
NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel r...
Source: businessinsider.com
NANOBIOTIX Provides Business Update and Financial Results
Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel...
Source: globenewswire.com
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
Reported €30.2 million in cash and cash equivalents as of March 31, 2023PARIS and CAMBRIDGE, Mass., May 17, 2023 -- NANOBIOTIX , a late-clinical stage biotechnology company pioneering... | May 17, 2023
United Kingdom France General United States Nord Pas De Calais New York University Of Texas Md Anderson Cancer Center
Source: marketscreener.com
Nanobiotix: CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3
Source: finanznachrichten.de
Nanobiotix: NANOBIOTIX Provides First Quarter Operational and Financial Update
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3
Source: finanznachrichten.de
NANOBIOTIX Provides First Quarter Operational and Financial Update
18.05.2022 - Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational ... Seite 1
Drug Administration First Quarter Operational Financial Update Registration Pathway Neck Cancer Local Control
Source: wallstreet-online.de